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Abstract
The risk assessment of the genetic susceptibility to cancer is the process of addressing 
and communicating the genetic risks to individuals and families with cancer. The recent 
breakthroughs of the next-generation sequencing era are adding new challenges to the 
precision clinical care.
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1. Introduction
New molecular biology technologies, such as whole-exome and whole-genome sequencing have 
been shedding new light on the understanding of inherited cancer susceptibility. At the same 
time, translational oncology researches on somatic and germline mutations in actionable genes 
have been opening new dilemmas of the next-generation sequencing era. A critical issue of the 
so-called precision medicine is the genetic counseling of individuals with cancer susceptibility.
Susceptibility to cancer depends on the penetrance of germline variants or inherited alleles, 
which may be classified into three groups such as highly penetrant, moderately penetrant and 
lowly penetrant alleles.
Alleles with high penetrance have the highest lifetime risk of cancer, frequently more than 10 
times the relative risk, dramatically affecting the quality of life and decreasing its expectancy. 
More than 50 rare Mendelian cancer syndromes are caused by germline mutations affecting 
either tumor suppressor genes, DNA repair genes or proto-oncogenes, mostly with autoso-
mal dominant inheritance (Table 1).
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Syndrome Gene Mutation status Penetrance Tumors
Hereditary breast and/or 
ovarian cancer
BRCA1 Heterozygous High Breast cancer
BRCA2 Ovarian cancer
RAD51 (B,C,D) Moderate Pancreatic cancer
ATM Moderate Prostate cancer
CHEK2 Moderate Colorectal cancer
Lynch syndrome MLH1 Heterozygous High Colorectal cancer
MSH2 Endometrial cancer
MSH6 Ovarian cancer
PMS2 Gastric cancer
EPCAM Leukemia, lymphoma
MMR cancer syndrome MMR genes Homozygous High Rhabdomyosarcoma
Familial adenomatous 
polyposis
APC Heterozygous High Gastrointestinal 
adenomas
Colorectal cancer
Duodenal cancer
MYH-associated polyposis MUTYH Homozygous High Colorectal cancer
Polymerase proofreading-
associated polyposis
POLE Heterozygous high Colorectal cancer
POLD1 Endometrial cancer
Bloom syndrome BLM1 Homozygous High Leukemia
Colorectal cancer
Wilms tumor
Nijmegen syndrome NBS1 Homozygous High Lymphoma
Medulloblastoma
Rhabdomyosarcoma
Fanconi anemia FANC genes (includes 
BRCA2, PALB2, 
BRIP1)
Homozygous High Leukemia
Medulloblastoma
Wilms tumor
Li-Fraumeni syndrome TP53 Heterozygous High Breast cancer
Li-Fraumeni-like syndrome CHEK2 Moderate Sarcoma
Adrenocortical cancer
Brain tumor
Cowden syndrome PTEN Heterozygous High Hamartomatous polyps
Skin tumors
Breast cancer
Thyroid cancer
Endometrial cancer
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Syndrome Gene Mutation status Penetrance Tumors
Hereditary diffuse gastric 
cancer
CDH1 Heterozygous High Gastric cancer (diffuse)
Breast cancer (lobular)
Peutz-Jeghers syndrome STK11 Heterozygous High Hamartomatous polyps
Colorectal
Small bowel
Breast cancer
Pancreatic cancer
Juvenile polyposis SMAD4 Heterozygous High Hamartomatous polyps
BMPR1A Colorectal cancer
Pancreatic cancer
Melanoma syndromes CDKN2A Heterozygous High Malignant melanoma
CDK4 Pancreatic cancer
Neurofibromatosis NF1 Heterozygous High Vestibular schwannoma
NF2 Meningioma
Neurofibroma
Optic glioma
Tuberous sclerosis TSC1 Heterozygous High Renal angiomyolipoma
TSC2 Subependymoma
Giant cell astrocytoma
Von Hippel-Lindau 
syndrome
VHL Heterozygous High Hemangioblastomas
Renal cell cancer
Pheochromocytoma
Chuvash polycythemia Homozygous High Vertebral angiomas
Birt-Hogg-Dubè syndrome FLCN Heterozygous High Renal cell cancer
Skin tumors
Papillary renal cancer 
syndromes
FH Heterozygous High Renal cell cancer
MET
Retinoblastoma RB1 Heterozygous High Retinoblastoma
Hereditary Paraganglioma SDH (A, B, C, D) Heterozygous High Paraganglioma
Pheochromocytoma
Multiple endocrine 
neoplasia 1
MEN1 Heterozygous High Pituitary adenoma
Multiple endocrine 
neoplasia 2
RET Parathyroid adenoma
Medullar thyroid cancer
Pheochromocytoma
Table 1. Hereditary cancer syndromes.
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Alleles with moderate or intermediate penetrance increase the relative risk of about two to 
five times. Although they are rare in most populations, they may be frequently found in pop-
ulations with consanguineous families due to founder effects. Affected relatives can be often 
identified, but the reduced penetrance of the alleles may skip generations and jeopardizes the 
family history.
Lowly penetrant alleles were discovered by genome-wide association studies (GWAS) and 
may put individuals to risk of cancer at slightly higher rates than those of the general popu-
lation. This is due to a polygenic model, in which several alleles, mainly single nucleotide 
polymorphisms (SNPs), each one carrying a low risk, combine additively or multiplicatively 
to confer a range of risks in the population. In this model, individuals with few alleles would 
be at a reduced risk, whereas those with many alleles might suffer a lifetime risk as high 
as 50% [1]. It is estimated that more than 100 common variants with low risk may contrib-
ute to cancer susceptibility. Actually, they explain part of the excess familial risk, and the 
so-called “missing heritability” remains largely unknown [2]. Thus, it is very important to 
identify lowly penetrant alleles responsible for cancer genetic susceptibility. Most of these 
alleles are intergenic—lie between genes—and many neighbor tumor suppressor genes and 
proto-oncogenes, possibly affecting their expression. Nowadays, with the advance of next-
generation sequencing and genotyping assays, more variants have been identified, shedding 
new light on the genomic architecture of the inherited susceptibility of cancer.
2. Risk assessment of the genetic susceptibility to cancer
The risk assessment of the genetic susceptibility to cancer (RAGSC) is a process to evalu-
ate a personal risk of carrying a germline variant that is associated to the cancer develop-
ment. RAGSC may be performed through statistical models that incorporate factors such 
as personal and familial history of tumors, ethnic background, and so on [3]. The advent 
of new sequencing technologies and bioinformatics has led to improvements of estimat-
ing more precisely risks of germline variants in many genes and assessing empiric risks 
of cancer.
Being part of this dynamic process [4], genetic counseling involves the analysis of pedigrees 
and risk assessment models to determine whether a family history is suggestive of sporadic, 
familial or hereditary cancer [5]. The main goal of genetic counseling is to inform susceptible 
individuals about their chances of developing cancer, helping them to make decisions about 
genetic testing, screening, prevention and treatments. Pretest and posttest genetic counseling 
are essential for the efficacy of implementing evidence-based protocols, in terms of reducing 
mortality rates [6].
Table 2 summarizes the RAGSC process. Three main risk categories can be derived on the 
basis of patient and family genetic information. In the low-risk category (near-population 
risk), management is based on population screening, and genetic tests are generally not cost-
effective; in the moderate-risk group, genetic counseling, genetic testing and management 
are individual-based; in the high-risk group, genetic counseling, testing and management are 
evidence-based and improve survival [7].
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3. Referrals for RAGSC
Besides sex and age, familial history is the main unmodifiable risk factor of developing cancer.
Assessing the risk factors of cancer in an individual or family is complex and raises psycho-
logical, social and ethical issues. It requires the understanding of areas of medical genetics 
Average risk High Moderate/intermediate Low/populational
Personal/family history Mendelian syndromes Familial aggregation Sporadic
Genetic testing Single gene sequencing/NGS 
panels/WGS/WES
NGS panels/WGS/WES DTC&/WGS/SNP 
genotyping
Genetic counseling Mandatory Advisable Available
Management Evidence-based Individual-based1 Not validated
DTC: direct-to-consumer tests; WGS: whole-genome sequencing; WES: whole-exome sequencing.
1Some evidence-based screening recommendations exist for breast and colorectal cancers.
&Restricted by the US Food and Drug Administration.
Table 2. Overview of the risk assessment of the genetic susceptibility to cancer.
Personal history
Early onset of cancer diagnosis (e.g., breast cancer <45 years, colorectal cancer <50 years)
Multiple associated primary cancers: breast/ovary, colorectal/endometrium
Male breast cancer
Ovarian, fallopian tube, primary peritoneal cancer
Breast cancer and thyroid, sarcoma, adrenocortical carcinoma
Multiple colon polyps (>10 cumulative)
Colorectal or endometrial cancer with microsatellite instability and/or lack of expression of mismatch repair 
protein(s) by immunohistochemistry
Family history
Three close relatives (same side of family) with cancer of the same or syndromically related type (breast/ovary, 
colorectal/endometrium)
Two close relatives (same side of family) with cancer of the same or related type with at least one affected under 
50 years
One first-degree relative with early onset cancer (breast <45 years, colorectal <50 years)
One fist-degree relative with multiple primary cancers
Two or more relatives with uncommon cancers (sarcoma, glioma, hemangioblastoma, etc.)
Relatives of patients with known BRCA, APC, MYH, Lynch syndrome mutations
Many relatives with cancer but no criteria for testing
Table 3. Referrals for hereditary cancer risk assessment.
Challenges and Perspectives of the Risk Assessment of the Genetic Susceptibility to Cancer…
http://dx.doi.org/10.5772/intechopen.72379
261
and oncology, besides the ability of communication, and it demands more time than just 
a regular consultation. The American Society of Clinical Oncology (ASCO), the National 
Society of Genetic Counselors (NSGC) and the Oncology Nursing Society (ONS) have pub-
lished guidelines for the practice of genetic counseling, risk assessment and genetic test-
ing [6, 8]. Moreover, it includes management of at-risk individuals so that they can make 
informed choices about cancer screening, prevention and targeted therapies [9]. In Table 3, 
there are some indications of referral for RAGSC.
4. Next-generation sequencing
In 2013, at first, Roberts and Klein reported the use of next-generation sequencing (NGS) to 
identify a hereditary cancer syndrome. They found pathogenic germline variants in the ATM 
gene of six pancreatic cancer relatives from two different kindreds [10]. Jaeger et al. used 
whole-genome sequencing for the description of hereditary mixed polyposis syndrome [11].
More recently, multigene NGS panels have been used to analyze many highly and moderately 
penetrant variants. Although they use the same NGS technology, there is less information on 
predefined genes. In comparison with single-gene sequencing, panels are more time- and 
cost-efficient in many cases such as (1) when there is genetic or locus heterogeneity, (2) when 
there are actionable mutations in several genes and (3) when phenotype or family history is 
too unspecific or noninformative (e.g., adoption) [12].
One advantage of NGS is the possibility of including multiple genes in panels tailored to a 
certain familial aggregation of tumors such as breast or colon cancer. However, because of its 
economic viability, NGS has shifted the phenotype-driven hypothesis approach that is based 
on the characteristics of the syndrome. Slavin et al. found some interesting results about mul-
tigene panels. When they included only high-risk genes, the results were seldom positive, and 
there were more variants of unknown significance (VUS), probably because of the inclusion of 
more genes in the so-called “off-phenotype” pan-cancer panels [13]. Recently, evidence-based 
guidelines have included the utilization of multigene testing for hereditary breast and ovarian 
cancer risk assessment [14].
An important disadvantage of NGS is the probability of disclosing inconclusive or undeter-
mined results. The interpretation of a VUS based on phenotype and genotype data is a diffi-
cult task and often jeopardizes the genetic counseling process. Choosing a panel with limited 
genes of high clinical utility specifically driven to the phenotype instead of pan-cancer panels 
with many low-risk genes can diminish the chances of finding variants with stressful inter-
pretation [13]. Moreover, databases of variants with high and moderate risks are often not 
population-specific and may lead to misinterpretation of results.
Some ethical challenges are critical for implementing NGS in the clinics.
In March 2013, the American College of Medical Genetics and Genomics (ACMG) published rec-
ommendations on the reporting of incidental or secondary findings from NGS. The ACMG sug-
gested the identification of 56 genes whose variants result in a high risk of developing a severe 
disease. Germline mutations of 16 of these genes cause hereditary cancer syndromes (Table 4) [15].
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In 2015, the ACMG reviewed it based on the consensus that patients could opt out of the 
analysis of secondary findings. This decision must be made during the process of informed 
consent, before testing. As some of these cancer syndromes may have the onset during child-
hood, these guidelines may also be applied to children, whose parents should make the deci-
sion whether or not to opt out [16].
A recent review showed that following the recommendations of international human genetic 
societies, parents and their children must be previously informed by a written consent about 
which findings should be reported. The ordering clinician must discuss with the children´s 
parents all the possibilities of results, including the reporting of incidental findings, the “right 
not to know,” the risks and the benefits, as well is responsible to obtain the informed consent 
and to provide pre- and posttest genetic counseling [17].
5. Conclusions
Inevitably, more challenges will arise with the application of NGS in RAGSC.
First, pretest counseling and informed consent models need to be redesigned to address the 
multiplex testing. Novel approaches must be developed to ensure that individuals under-
stand the risks and benefits of choices regarding these tests. Second, the clinical management 
of carriers of moderately penetrant variants is still poorly defined, although some evidence-
based guidelines may include them [14]. Third, finding VUS is always a potential risk, and 
such identification complicates data interpretation and often requires further investigation 
and variant reclassification. In addition, management of patients with VUS is unclear. Finally, 
many hereditary cancer syndromes have locus heterogeneity, incomplete penetrance and 
may represent phenocopies, adding difficulty in RAGSC.
Syndrome Gene
Li-Fraumeni TP53
Peutz-Jeghers STK11
Familial adenomatous polyposis APC
Von-Hippel Lindau VHL
Multiple endocrine neoplasia MEN1 (type 1); RET (type 2)
Hamartomatosis PTEN
Retinoblastoma RB
Paraganglioma-pheochromocytoma SDHAF2, SDHB, SDHC, SDHD
Tuberous sclerosis complex TSC1, TSC2
Neurofibromatosis type 2 NF2
WT1-related Wilms tumor WT1
Table 4. ACMG list of hereditary cancer syndromes.
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In summary, the biggest challenge in counseling families with cancer is conferring precise 
information regarding genetic susceptibilities because it allows a better informed decision-
making process about risk management, clinical surveillance, targeted therapies and preven-
tive measures.
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